243 related articles for article (PubMed ID: 28847226)
41. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
[TBL] [Abstract][Full Text] [Related]
42. Recommendation for subclass evaluation of TNM stage iva papillary thyroid carcinomas: T4aN1b patients are at risk for recurrence and survival.
Wada N; Masudo K; Nakayama H; Suganuma N; Matsuzu K; Hirakawa S; Rino Y; Masuda M; Imada T
Ann Surg Oncol; 2008 May; 15(5):1511-7. PubMed ID: 18299932
[TBL] [Abstract][Full Text] [Related]
43. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
44. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
45. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
[TBL] [Abstract][Full Text] [Related]
46. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
47. Prognostic implications of extranodal extension in papillary thyroid carcinomas: A propensity score matching analysis and proposal for incorporation into current tumor, lymph node, metastasis staging.
Genpeng L; Pan Z; Tao W; Rixiang G; Jingqiang Z; Zhihui L; Jianyong L
Surgery; 2022 Feb; 171(2):368-376. PubMed ID: 34482990
[TBL] [Abstract][Full Text] [Related]
48. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
[TBL] [Abstract][Full Text] [Related]
49. Long-term outcome of thyroid lobectomy for unilateral multifocal papillary carcinoma.
Huang H; Liu S; Xu Z; Ni S; Zhang Z; Wang X
Medicine (Baltimore); 2017 Jul; 96(27):e7461. PubMed ID: 28682915
[TBL] [Abstract][Full Text] [Related]
50. Improving postoperative recurrence rates for carcinoma of the thyroid gland.
McHenry C; Jarosz H; Lawrence AM; Paloyan E
Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
52. Impact of surgical resection extension on outcome for primary well-differentiated thyroid cancer-a retrospective analysis.
Muller S; Senne M; Kirschniak A; Königsrainer A; Bares R; Falch C
World J Surg Oncol; 2017 Oct; 15(1):190. PubMed ID: 29065879
[TBL] [Abstract][Full Text] [Related]
53. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
54. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome.
Radowsky JS; Howard RS; Burch HB; Stojadinovic A
Thyroid; 2014 Feb; 24(2):241-4. PubMed ID: 23713855
[TBL] [Abstract][Full Text] [Related]
55. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T
Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980
[TBL] [Abstract][Full Text] [Related]
56. Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system.
Chereau N; Oyekunle TO; Zambeli-Ljepović A; Kazaure HS; Roman SA; Menegaux F; Sosa JA
Br J Surg; 2019 Jun; 106(7):889-897. PubMed ID: 31012500
[TBL] [Abstract][Full Text] [Related]
57. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
58. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
59. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma.
Roh JL; Park JW; Jeong J; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2017 Sep; 116(4):450-458. PubMed ID: 28608492
[TBL] [Abstract][Full Text] [Related]
60. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.
Zidan J; Karen D; Stein M; Rosenblatt E; Basher W; Kuten A
Cancer; 2003 Mar; 97(5):1181-5. PubMed ID: 12599223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
